Vifor Pharma Group Announces Successful Sale of OM Pharma
18.9.2020 08:00:00 EEST | Business Wire | Press release
Regulatory News:
Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include:
- A purchase consideration of MCHF 435 for 100% of the share capital
- An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple
This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days.
OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.
Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries and exporting to 60 countries worldwide, as a strategic partner. Optimus Holding is fully committed to the sustainable growth of OM Pharma and to invest considerably in R&D to become a global biotechnology company focused on improving the lives of patients with respiratory and inflammatory diseases.
Stefan Schulze, CEO of Vifor Pharma Group comments, “I am very pleased to have successfully completed the competitive sale process of OM Pharma announced earlier this year that was overseen by Rothschild & Co. Optimus Holding Ltd. brings a wealth of expertise and OM Pharma will benefit from the knowledge, financial investment and operational synergies of the new owners. This sale strengthens our strategic focus and will enable the company to further invest into our exciting product pipeline, especially in our core therapeutic area of nephrology.”
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is the partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma. Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005959/en/
Contact information
Vifor Pharma Group:
Media Relations
Nathalie Ponnier
Global Head of Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
Optimus Holding Ltd.:
Beatrix Benz
+41 79 256 77 73
beatrix.benz@benz-advisory.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TradingHub Secures Strategic Investment From Nordic Capital to Accelerate Next Phase of Growth16.3.2026 18:00:00 EET | Press release
TradingHub, a leading provider of trade surveillance technology for global financial institutions, has agreed to partner with Nordic Capital which will become the company’s majority shareholder. The investment marks a significant milestone in TradingHub’s journey and provides strong backing to support the company’s continued growth and innovation. Existing investor Summit Partners and TradingHub’s co-founder Neil Walker will continue to hold minority positions in the company following the close of the transaction. With the support of Nordic Capital, TradingHub will accelerate its expansion across global markets while continuing to invest in the development of its trade surveillance platform. The company plans to further strengthen its capabilities across asset classes, including equities, and continue its expansion into new markets and geographies. Founded in 2010 and today operating from offices in London, Toronto, Singapore and Sydney, TradingHub has built a highly differentiated tec
Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation16.3.2026 17:10:00 EET | Press release
The third edition of the Umrah and Ziyarah Forum will commence in Madinah on Monday, March 30, 2026. The forum is organized by the Ministry of Hajj and Umrah, in partnership with the Pilgrim Experience Program, at the King Salman International Convention Center, with wide participation from business leaders, decision-makers, and specialists in the Umrah and Ziyarah services ecosystem from around the world to exchange expertise and explore ways to further enrich the experience of the Guests of Allah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316471639/en/ Madinah Hosts Third Umrah and Ziyarah Forum with Strong International Participation (Photo: AETOSWire) This year’s edition builds on the success of the forum's previous editions, reaffirming its position as a global platform for advancing the Umrah and Ziyarah services ecosystem. It focuses on enhancing services for Umrah performers and visitors, in line with the gro
Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 15:00:00 EET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Resident Evil Requiem in 2026, and orchestral concerts in Japan,
Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 15:00:00 EET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the company will continue to offer a grand prize of $1 million for Capcom Cup and will increase the total prize pool for Street Fighter League from $200,000
Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 15:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (energization) tests in 2027. It also highlights Helical Fusion’s role in leading a “Japan-style public–private partnership (PPP)” for fus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom